Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | SGK1 | O00141 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25047169 | 0.74 | HSP90AA1 (0.35) | ALDH1A1NOS1DYRK1ASGK1HSP90AA1 | |
| SCHEMBL19153595 | 0.74 | CDK1 (0.46) | ALDH1A1DYRK1ASGK1HSP90AA1IDO1 | |
| SCHEMBL25207314 | 0.74 | RET (0.41) | ALDH1A1DYRK1ASGK1HSP90AA1IDO1 | |
| SCHEMBL10758 | 0.73 | NOS1 (0.47) | ALDH1A1NOS1DYRK1AHSP90AA1IDO1 | |
| SCHEMBL29480802 | 0.73 | NOS1 (0.47) | ALDH1A1NOS1DYRK1AHSP90AA1IDO1 | |
| SCHEMBL2967092 | 0.72 | MAPK1 (0.48) | ALDH1A1DYRK1ANUDT1MAPK1 | |
| SCHEMBL23074994 | 0.69 | CCR1 (0.38) | ALDH1A1NOS1DYRK1ASGK1HSP90AA1 | |
| SCHEMBL18237617 | 0.69 | ALDH1A1 (0.33) | ALDH1A1DYRK1ASGK1HSP90AA1IDO1 | |
| SCHEMBL9978592 | 0.68 | ALDH1A1 (0.43) | ALDH1A1CDK2KDM4E | |
| SCHEMBL219870 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118772157-A | Synthesis method of 6-chloro-1H-pyrazolo [3,4-B ] pyrazine | 浙江江北南海药业有限公司 | 2024-10-15 | — | — | CN | claimed |
| WO-2015013783-A1 | HAIR CARE COMPOSITION COMPRISING AMINO SILICONE AND PHOSPOLIPIDE POLYMERS | L'OREAL (FR) | 2015-02-05 | — | — | WO | claimed |
| CN-117683033-B | Substituted alkynyl heterocyclic compounds | Capital Pharmaceutical Holdings (Beijing) Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-16 | — | — | US | disclosed |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4646416-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646413-A1 | SOLID FORMS OF A CDK2 INHIBITOR | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| US-12458640-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2018081091-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018057884-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018057884-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-9738648-B2 | Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-08-22 | — | — | US | disclosed |
| US-20170226113-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-10 | — | — | US | disclosed |
| EP-3049417-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2016-08-03 | — | — | EP | disclosed |
| US-20160159804-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| WO-2015013783-A1 | HAIR CARE COMPOSITION COMPRISING AMINO SILICONE AND PHOSPOLIPIDE POLYMERS | L'OREAL (FR) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015017502-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226113-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | ALDH1A1 4081/4885NOS1 3777/4885DYRK1A 228/4885 |
| US-12458640-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors | PTPN5, PTPRZ1, PTPN1 | ALDH1A1 2209/4885NOS1 3679/4885DYRK1A 441/4885 |
| US-20160159804-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | ALDH1A1 4081/4885NOS1 3777/4885DYRK1A 228/4885 |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ALDH1A1 3983/4885NOS1 4439/4885DYRK1A 4519/4885 |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | PTPN5, PTPN1, PTPN3 | ALDH1A1 1802/4885NOS1 3183/4885DYRK1A 237/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | ALDH1A1 1507/4885NOS1 4710/4885DYRK1A 2261/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | ALDH1A1 2433/4885NOS1 4331/4885DYRK1A 1319/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | ALDH1A1 3280/4885NOS1 3611/4885DYRK1A 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.